Ultimovacs 과거 수익 실적

과거 기준 확인 0/6

Ultimovacs의 수입은 연평균 -16.8%의 비율로 감소해 온 반면, Biotechs 산업의 수입은 연간 증가했습니다(7.7%).

주요 정보

-16.8%

수익 성장률

-11.2%

EPS 성장률

Biotechs 산업 성장	20.9%
매출 성장률	n/a
자기자본 수익률	-78.2%
순이익	n/a
다음 실적 업데이트	13 Feb 2025

최근 과거 실적 업데이트

Recent updates

Here's Why We're Not At All Concerned With Ultimovacs' (OB:ULTI) Cash Burn Situation

Jul 27

We're Hopeful That Ultimovacs (OB:ULTI) Will Use Its Cash Wisely

Mar 23

Have Insiders Sold Ultimovacs ASA (OB:ULTI) Shares Recently?

Feb 13

수익 및 비용 분석

Ultimovacs 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

OB:ULTI 수익, 비용 및 수입 (NOK Millions )
날짜	수익	G+A 비용
30 Sep 24	-149	55
30 Jun 24	-179	61
31 Mar 24	-178	61
31 Dec 23	-189	61
30 Sep 23	-204	59
30 Jun 23	-186	57
31 Mar 23	-165	59
31 Dec 22	-168	57
30 Sep 22	-148	58
30 Jun 22	-153	54
31 Mar 22	-168	51
31 Dec 21	-165	47
30 Sep 21	-138	47
30 Jun 21	-126	46
31 Mar 21	-124	49
31 Dec 20	-121	46
30 Sep 20	-121	39
30 Jun 20	-108	39
31 Mar 20	-77	19
31 Dec 19	-61	17
30 Sep 19	-48	15
30 Jun 19	-48	16
31 Mar 19	-59	25
31 Dec 18	-55	24
30 Sep 18	-50	23
30 Jun 18	-42	18
31 Mar 18	-35	17
31 Dec 17	-33	17
31 Dec 16	-29	13

양질의 수익: ULTI 은(는) 현재 수익성이 없습니다.

이익 마진 증가: ULTI 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: ULTI 은(는) 수익성이 없으며 지난 5년 동안 연간 16.8% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 ULTI 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: ULTI 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( -18.2% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: ULTI 현재 수익성이 없기 때문에 마이너스 자본 수익률( -78.15% )을 갖습니다.

Ultimovacs 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Ultimovacs ASA to Report Q4, 2024 Results on Feb 13, 2025

Ultimovacs ASA to Report Q1, 2021 Results on May 11, 2021

Recent updates

Ultimovacs ASA Announces Publication of Phase II FOCUS Trial Results on MedRxiv

New major risk - Market cap size

Ultimovacs ASA Announces Resignation of Ketil Fjerdingen as Deputy Board Member

Ultimovacs ASA Announces Topline Data from FOCUS Phase II Trial of UV1 Combined with Pembrolizumab in Patients with Metastatic or Recurrent Head and Neck Cancer

Ultimovacs Asa Announces Poster Presentation of Nipu Phase II Trial Update At Upcoming ESMO Congress 2024

Ultimovacs Asa Provides Update from Phase I Study in Malignant Melanoma

No longer forecast to breakeven

New major risk - Revenue and earnings growth

Ultimovacs ASA Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program

Price target decreased by 8.6% to kr155

New minor risk - Market cap size

Ultimovacs Announces Topline Results from INITIUM Study Evaluating UV1 Vaccination Added to Ipilimumab and Nivolumab in Patients with Unresectable or Metastatic Malignant Melanoma

New minor risk - Share price stability

Companies Like Ultimovacs (OB:ULTI) Can Afford To Invest In Growth

Ultimovacs Receives FDA Fast Track Designation for UV1 Cancer Vaccine for the Treatment of Patients with Unresectable Mesothelioma

Ultimovacs ASA Updates Timeline for Reporting on Randomized UV1 Phase II Trial Initium in Malignant Melanoma

Ultimovacs ASA to Report Q4, 2024 Results on Feb 13, 2025

Insufficient new directors

Ultimovacs ASA Announces Resignation of Aitana Peire from Board of Directors

Ultimovacs ASA Announces Resignation of Aitana Peire from Board of Directors

Chief Executive Officer recently bought kr57k worth of stock

No longer forecast to breakeven

Ultimovacs ASA Announces Completion of Patient Enrollment in Supplementary Study to INITium, UV1 Phase II Trial in Malignant Melanoma

Ultimovacs ASA Announces Protocol Amendment in UV1 Phase II Study INITIUM in Malignant Melanoma, Enabling Data Readout in First Half of 2024

Ultimovacs (OB:ULTI) Is In A Strong Position To Grow Its Business

Ultimovacs ASA Announces Full Dataset from the NIPU Clinical Trial (Nct04300244) Presented At the ESMO Congress 2023 in Madrid

Ultimovacs ASA Announces the Results from the NIPU clinical trial (NCT04300244)

New minor risk - Share price stability

Ultimovacs Provides 4-Year Update from Phase I Study in Malignant Melanoma: Demonstrating Sustained Long-Term Overall Survival in Patients Treated with Uv1 Cancer Vaccine

Ultimovacs ASA Receives FDA Orphan Drug Designation for the Uv1 Cancer Vaccine for Treatment of Mesothelioma

Ultimovacs ASA Announces the Results from Uv1 Phase Ii Clinical Trial Nipu in Malignant Mesothelioma Will Be Presented At the Esmo Congress 2023

Ultimovacs Announces Completed Enrollment in FOCUS Phase II Clinical Trial of UV1 in Head and Neck Cancer Patients

Ultimovacs ASA Announces Publication in Clinical Cancer Research of the UV1-103 Phase I Malignant Melanoma Trial Results

Ultimovacs Provides 3-Year Update from Phase I Study in Malignant Melanoma: Results Confirm Strong Overall Survival in Patients Treated with UV1 Cancer Vaccine

New minor risk - Share price stability

Ultimovacs ASA Provides Update on Phase II NIPU Trial Evaluating UV1 in Second-Line Patients with Malignant Leural Mesothelioma

No longer forecast to breakeven

Ultimovacs ASA Announces Completion of Patient Recruitment in NIPU Phase II Clinical Trial of UV1 in Mesothelioma

Ultimovacs ASA, Annual General Meeting, Apr 18, 2024

Ultimovacs ASA Announces Cemiplimab to Replace Pembrolizumab in V1 Phase II LUNGVAC Trial

Ultimovacs ASA Completes Last Patient Enrollment in Phase I TENDU Trial in Prostate Cancer

Chief Executive Officer recently bought kr145k worth of stock

Forecast to breakeven in 2023

No independent directors

No longer forecast to breakeven

Ultimovacs Announces First Patient Randomized in Phase II LUNGVAC Trial of UV1 in Non-Small Cell Lung Cancer (NSCLC)

Ultimovacs Asa Announces New Uv1 Data Showing Enhanced Efficacy Including in Hard-To-Treat Cancer Patients, Supporting Broad Utility

Ultimovacs Asa Announces New Uv1 Data Showing Enhanced Efficacy Including in Hard-To-Treat Cancer Patients, Supporting Broad Utility

Ultimovacs ASA Announces Positive Three-Year Results of 71% Overall Survival Rate in Cohort 1 of UV1-103 Study in Metastatic Malignant Melanoma

Companies Like Ultimovacs (OB:ULTI) Are In A Position To Invest In Growth

Ultimovacs ASA Announces Publication of Phase I Melanoma Trial Data in Journal of Translational Medicine

Chief Executive Officer recently bought kr134k worth of stock

Price target increased to kr151

Ultimovacs ASA Expands High Dose Cohort Size in Tendu Phase I Prostate Cancer Trial After Safety Review

Ultimovacs Completes Patient Recruitment in INITIUM Phase II Trial of UV1 in Malignant Melanoma

Ultimovacs ASA Announces UV1 Cancer Vaccine Shows Strong Overall Survival in Malignant Melanoma Phase I Trial

Ultimovacs (OB:ULTI) Is In A Good Position To Deliver On Growth Plans

Ultimovacs Announces Presentation of UV1 Immune Monitoring Data At Cancer Immunotherapy Annual Meeting

Price target increased to kr151

No independent directors

Ultimovacs ASA Approves Board and Committee Changes

Ultimovacs Presents TET Platform Pre-Clinical Data at AACR 2022 Supporting Clinical Development

Chief Executive Officer recently bought kr94k worth of stock

Ultimovacs ASA Completes Treatment of the Second Dose Cohort in the Phase I TENDU Trial

Ultimovacs ASA Announces First Patient Enrolled in Phase II DOVACC Trial of UV1 in Advanced Ovarian Cancer

Chief Executive Officer recently bought kr228k worth of stock

Ultimovacs Asa Announces Further Positive Topline Results from Phase I Uv1 Cancer Vaccine Combination Study in Metastatic Melanoma

Ultimovacs Announces First Patient Enrolled in Phase II Focus Trial of UV1 in Head-And-Neck Cancer

Here's Why We're Not At All Concerned With Ultimovacs' (OB:ULTI) Cash Burn Situation

Ultimovacs’ Announces Review Article Highlighting Telomerase-based Therapeutic Cancer Vaccines

Ultimovacs ASCO Phase I data shows 60% ORR in advanced melanoma with UV1/pembrolizumab, supporting broad Phase II combination program

Ultimovacs ASA Announces Publication in The Journal of Translational Medicine on Mechanistic Rationale of UV1 Cancer Vaccine Supporting Phase 2 Study Design in Malignant Mesothelioma

Deputy Board Member recently bought kr388k worth of stock